Odyssey Evaluation in Post LASIK Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-18

Study Completion Date

2026-08-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study evaluates the visual and refractive outcomes of the TECNIS Odyssey intraocular lens (IOL) implanted in patients with a history of myopic LASIK. Given the unique optical challenges of post-LASIK eyes, including altered corneal curvature and higher-order aberrations, the study aims to assess the IOL's performance in terms of distance, intermediate, and near vision, and patient satisfaction. Its design features may offer favorable outcomes in these patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Outcomes With Bilateral Implantation of Odyssey IOLs

NCT06550375

Cataract

COMPLETED

RLE Outcomes With Bilateral Implantation of Odyssey IOLs

NCT06979557

Refractive Lens Exchange

RECRUITING

Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL

NCT05991960

Cataracts

COMPLETED

User Acceptability Evaluation of Pseudophakic Patients Previously Implanted With the TECNIS Odyssey IOL

NCT06005675

Cataracts

COMPLETED

Visual Outcomes of Tecnis Symfony Opti-Blue EDOF Intraocular Lens (IOL)

NCT06500416

Cataract

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Odyssey IOL

Group Type OTHER

Odyssey intraocular lens

Intervention Type DEVICE

The Odyssey intraocular lens is intended to be implanted at the time of cataract surgery to replace the natural lens.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Odyssey intraocular lens

The Odyssey intraocular lens is intended to be implanted at the time of cataract surgery to replace the natural lens.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects MUST fulfill the following conditions to qualify for enrollment into the trial

1. Age: 50 years and older.
2. Gender: Males and Females.
3. Bilateral cataracts
4. Bilateral implantation of Odyssey IOLs (toric and non-toric)
5. Scheduled to undergo standard cataract surgery in both eyes, within 1 to 30 days between surgeries.
6. Willing and able to provide written informed consent for participation in the study.
7. Willing and able to comply with scheduled visits and study examination procedures.
8. Postoperative best corrected visual acuity of 0.2 logMAR (20/32 Snellen) or better in each eye.

Exclusion Criteria

Subjects with ANY of the following conditions on the eligibility exam may NOT be enrolled into the trial.

1. Established ocular pathology, including: glaucoma (except glaucoma suspects), uveitis, and clinically-significant retinal pathology affecting the macula (with visual acuity worse than 20/25) and/or any other ocular findings that may, in the opinion of the investigator, affect vision.
2. Uncontrolled diabetes.
3. Use of any systemic or topical drug known to interfere with visual performance.
4. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
5. Clinically significant corneal dystrophy.
6. Contact lens use during the active treatment portion of the trial.
7. Irregular astigmatism.
8. Corneal irregularities potentially affecting visual acuity (i.e., keratoconus, corneal opacities
9. History of chronic intraocular inflammation.
10. History of retinal detachment.
11. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
12. Previous intraocular surgery.
13. Previous keratoplasty
14. Previous refractive surgery other than myopic LASIK or PRK (i.e., radial keratotomy, hyperopic LASIK, etc)
15. Severe dry eye.
16. Pupil abnormalities.
17. Subject who may reasonably be expected to require a secondary surgical intervention at any time during the study (other than YAG capsulotomy, i.e., LASIK).
18. Any clinically significant, serious, or severe medical or psychiatric condition that may interfere with the interpretation of study results.
19. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.
20. Inability to focus or fixate for prolonged periods of time (e.g., due to strabismus, nystagmus, etc.)
21. Abnormal iris

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates the patient is unsuitable for the trial.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No